Logo do repositório
 
Publicação

Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study

2025-12-23Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorMartínez-Martínez, Francisco José
dc.contributor.authorChiner-Oms, Álvaro
dc.contributor.authorFurió, Victoria
dc.contributor.authorHpGP Research Network
dc.contributor.authorYamaoka, Yoshio
dc.contributor.authorDekker, John P.
dc.contributor.authorMégraud, Francis
dc.contributor.authorBénéjat, Lucie
dc.contributor.authorDucournau, Astrid
dc.contributor.authorGiese, Alban
dc.contributor.authorJehanne, Quentin
dc.contributor.authorJauvain, Marine
dc.contributor.authorCamargo, M. Constanza
dc.contributor.authorComas, Iñaki
dc.contributor.authorLehours, Philippe
dc.date.accessioned2026-02-20T10:43:25Z
dc.date.available2026-02-20T10:43:25Z
dc.date.issued2025-12-23
dc.descriptionHpGP Research Network: Mónica Oleastro (Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa, Portugal)
dc.description.abstractBackground: Rising antimicrobial resistance of Helicobacter pylori is a public health challenge. Genomic-based susceptibility testing allows for the identification of resistance-associated mutations, complementing conventional diagnostics and advancing towards pathogen-based personalised therapies. Our study aimed to identify genes and mutations involved in antimicrobial resistance in H pylori and evaluate the extent to which these markers can be used as predictors of phenotypic resistance against clarithromycin and levofloxacin. Methods: In this retrospective phenotypic and genotypic observational study, we included 1011 H pylori whole-genome sequences and strains of known geographical origin from the H pylori Genome Project (HpGP) collection. We performed phenotypic clarithromycin and levofloxacin susceptibility testing on a subset of 419 HpGP strains using Etest at a centralised laboratory. A genomic analysis was conducted to identify 23S rRNA and gyrA variants and build a curated catalogue of mutations associated with resistance to clarithromycin (ie, 23S rRNA 2142A→G, 2142A→C, and 2143A→G) and levofloxacin (ie, gyrA A88V or A88P, N87K or N87I, and D91G, D91N, or D91Y). Genotype-phenotype concordance was assessed to estimate sensitivity and specificity, and the curated catalogue of resistance-associated mutations was applied to the complete HpGP set. Region-specific prevalence of resistance-associated mutations was calculated for a combined dataset including the HpGP genomes and 768 whole-genome sequences retrieved from the US National Center for Biotechnology Information Sequence Read Archive repository. Associations between resistance genotypes, H pylori subpopulations, and minimum inhibitory concentrations (MICs) were tested. Findings: Clarithromycin-resistant and levofloxacin-resistant HpGP strains were estimated with a sensitivity and specificity of 100%, with all confidence intervals ranging from 96% to 100%. The combined analysis (n=1779) found the highest prevalence of clarithromycin resistance in the western Pacific region (173 [51·2%] of 338 in southeast Asia and 75 [29·8%] of 252 in eastern Asia), north African region (seven [38·9%] of 18), and western Asian region (12 [31·6%] of 38), whereas the highest prevalence of levofloxacin resistance was found in south Asia (14 [51·85%] of 27), Central America (48 [38·7%] of 124), eastern Europe (four [36·4%] of 11), and southern Africa (three [33·3%] of nine). Similarly, 23S rRNA and gyrA genotypes are variable across H pylori subpopulations. MIC values changed depending on the specific mutation in 23S rRNA (mean clarithromycin MIC 24·61 mg/L [95% CI 12·27-36·96] for 2143A→G and 142·25 mg/L [95% CI 77·88-206·61] for 2142A→G) and gyrA (mean levofloxacin MIC 9·66 mg/L [95% CI 6·75-12·56] for mutations on codon 91, and 27·97 mg/L [95% CI 25·82-30·11] for mutations on codon 87). Interpretation: Mutations in specific genes are reliable indicators to clarithromycin and levofloxacin resistance in H pylori, making them useful markers for the development of diagnostic assays and molecular monitoring. Our results suggest that using clarithromycin and levofloxacin empirically, without previous susceptibility testing, is unsuitable in all geographical regions covered by this study.eng
dc.description.sponsorshipThis work was supported in part by the intramural research programmes of the US National Library of Medicine, the US National Institute on Minority Health and Health Disparities, and the division of Intramural Research, US National Institute of Allergy and Infectious Diseases, NIH. FFV is funded by Fundação para a Ciência e a Tecnologia (FCT) through project grants (project PTDC/BTM-TEC/3238/2020 and CPCA-IAC/AV/478719/2022) that partially supported this work, alongside national funds from FCT projects UIDB/04138/2020, UIDP/04138/2020, and UIDB/04046/2020 (https://doi.org/10.54499/UIDB/04046/2020). The collaborating centres for sample collection received grant support from the US NIH (P01CA116087, R01CA077955, R01DK058587, and P30DK058404 to RMP; P01CA028842 and R01CA190612 to KTW; P01CA028842, R01CA190612, K07CA125588, R03CA167773, and P30CA068485 to DRM; K08CA252635 to RJH; K22CA226395 to MG-P; and U54GM133807 to MC-C), the German Federal Ministry of Education and Research (BMBF-0315905D, ERA-NET PathoGenoMics to PM), the French Association pour la Recherche Contre le Cancer (8412 to FM), the French Institut National du Cancer (07/3D1616/IABC-23–12/NC-NG and 2014–152 to FM), the Canceropole Grand Sud-Ouest (2010–08-canceropole GSO-Universite Bordeaux 2 to FM), the Japanese Ministry of Education, Culture, Sports, Science, and Technology (21H00346 221S0002, 22H02871, and 23K24133 to YY), the Japanese Adopting Sustainable Partnerships for Innovative Research Ecosystem (ASPIRE; 23jf0126006h0001 to YY), the National Fund for Innovation and Development of Science and Technology from the Ministry of Higher Education Science and Technology of the Dominican Republic (2012–2013–2A1–65 and 2015–3A1–182 to MC), the National Cancer Center of South Korea (2210630, IJC), ArcticNet (RES0010178 to KJG), the Network of Centres of Excellence of Canada, the Canadian Institutes for Health Research (MOP115031 to KJG), Alberta Innovates Health Solutions (201201159 to KJG), the University of Malaya-Ministry of Higher Education (UM.C/625/1/HIR/MOHE/CHAN-02 to JV), the Ministry of Science and Technology of Vietnam, the Kyrgyz State Medical Academy, the Italian Ministry of Health for Institutional Research, the Chilean National Fund for Health Research and Development (FONIS A19/0188, FONDECYT 1230504, and ANID-FONDAP 152220002 to AR; CONICYT-FONDAP 15130011 and FONDECYT 1231773 to AHC), the Chilean Cancer Prevention and Control Center, the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2014/26847–0, 2018/14267–2, 2018/02972–3 to ED-N), the Departamento de Ciência e Tecnologia (DECIT), Ministry of Health, Brazil (PRONON, SIPAR 2500·035–167/2015–23 to ED-N), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 314344/2020–9 to ET-S), the Universidad de Costa Rica (742-B9–310 and 742–90912–19 to VR-M), LABGIPAT (SD-B), the Hospital Clínica Bíblica (CC-N), the Greek Ministry of Culture and Education (InfeNeutra Project, NSRF 2007–2013, MIS450598, DNS), the National Strategic Reference Framework Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014–2020, MIS5002486, DNS), the Hellenic Publishing Helicobacter pylori Study Group (2012–2016, BM-G), the Hellenic Society of Gastroenterology (National Multicenter Laboratory Surveillance Studies, 2018–2019, BM-G), the Ministry of Science and Technology, Executive Yuan, Taiwan (109–2314-B-002–096; MOST 111–2314-B-002–012; and MOST 109–2314-B-002–090-MY3 to J-ML and M-SW), the National Research Foundation of Singapore, the Singapore Ministry of Health’s National Medical Research Council (Open Fund-Large Collaborative Grant, MOH-OFLCG18May-0003), the University of Puerto Rico Comprehensive Cancer Center, the Fondo Nacional de Desarrollo Científico y Tecnológico (196–2015-FONDECYT to CC), Universidad Científica del Sur, the Instituto Nacional de Enfermedades Neoplásicas (INEN, Peru), the European Research Council (ERC): H2020-ERC-COG/0800; Ministerio Español de Ciencia e Innovación: PID2022–137607OB-I00 and PRE2020–094308, and Prometeo Programme Generalitat Valenciana CIPROM2023 MICROGLOCAL received by IC, the RyC grant RYC2021-031461-I funded by MCIN/AEI/10·13039/501100011033 and by the “European Union NextGenerationEU/PRTR” received by ACO. ACO and IC are part of the CSIC’s Global Health Platform (PTI Salud Global).
dc.identifier.citationLancet Microbe. 2026 Jan;7(1):101217. doi: 10.1016/j.lanmic.2025.101217. Epub 2025 Dec 23
dc.identifier.doi10.1016/j.lanmic.2025.101217
dc.identifier.eissn2666-5247
dc.identifier.pmid41453373
dc.identifier.urihttp://hdl.handle.net/10400.18/10956
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relationResearch Institute for Medicines
dc.relationResearch Institute for Medicines
dc.relationBiosystems and Integrative Sciences Institute
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S2666524725001454?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHelicobacter Pylori
dc.subjectGenotypic Observational Study
dc.subjectClarithromycin-Resistant
dc.subjectLevofloxacin-Resistant
dc.subjectInfecções Gastrointestinais
dc.subjectResistência aos Antimicrobianos
dc.titleGenomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational studyeng
dc.typejournal article
dcterms.referenceshttps://www.sciencedirect.com/science/article/pii/S2666524725001454?via%3Dihub
dspace.entity.typePublication
oaire.awardTitleResearch Institute for Medicines
oaire.awardTitleResearch Institute for Medicines
oaire.awardTitleBiosystems and Integrative Sciences Institute
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FBTM-TEC%2F3238%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04138%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04138%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04046%2F2020/PT
oaire.citation.issue1
oaire.citation.startPage101217
oaire.citation.titleThe Lancet Microbe
oaire.citation.volume7
oaire.fundingStream3599-PPCDT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
relation.isProjectOfPublication896b5212-8f95-4c91-bdf9-070f1654cb5e
relation.isProjectOfPublicationfe981d64-0f63-4bb3-9872-613e531ce02d
relation.isProjectOfPublication0a697dbe-9b80-4602-8abe-045a0bb8ee75
relation.isProjectOfPublicationdc433369-36fd-4935-bd52-c56aa49c72e1
relation.isProjectOfPublication.latestForDiscovery896b5212-8f95-4c91-bdf9-070f1654cb5e

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1-s2.0-S2666524725001454-main.pdf
Tamanho:
4.78 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais